Strasbourg, 10 June 2021. SPARTHA Medical, French MedTech company specializing in the development of multifonctional antimicrobial, antiviral and anti-inflammatory coatings, is pleased to announce the registration of its patent in the formulation of polymer-based coatings in the United States (US10864296B2).


This patent relies on the biocidal effect of polyelectronic coatings, whose application can have a major impact in the reduction of nosocomial infections following the implantation of medical devices.


Founded in 2019 and based in Strasbourg, France, SPARTHA Medical is a preclinical-stage MedTech company, resulting from the work of Inserm unit U1121, which develops coatings based on natural components with antimicrobial, antiviral and anti-inflammatory properties. SPARTHA Medical’s ambition is to protect medical devices and all types of surfaces from infectious risks by offering easy-to-apply and multifunctional coating solutions.


Laureate of i-Lab in 2019, SPARTHA Medical want to be a leader on the market of personalized coatings. SPARTHA Medical is in incubated in SEMIA, is member of Biovalley France and has been part of a maturation project supported by SATT Conectus.

Fore more information, please contact us.

Comments are closed.